A phase I/II, open label trial of Lewis Y specific monoclonal antibody IGN311 to evaluate safety and efficacy in patients with malignant effusion This is an ASCO Meeting Abstract from the 2006 ASCO ...
Malignant pleural mesothelioma (MPM) is a primary and locally aggressive tumor of the pleura. A well defined causal relationship with asbestos exposure, and an overwhelming media interest in the use ...
Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Pleural Effusion Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ...
The FDA has cleared Becton Dickinson’s catheter system for the treatment of non-malignant, recurrent causes of pleural effusion, or the collection of fluid next to the lungs. This clearance expanded ...
Leading Malignant Pleural Effusion companies in the market include - RS Oncology, Genelux Corporation, Candel Therapeutics, and others. The Malignant Pleural Effusion Market is projected to experience ...
(MENAFN- GlobeNewsWire - Nasdaq) The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results